Edgewise Therapeutics Inc. Common Stock vs TechnipFMC plc Ordinary Share — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.11 (market cap $3.94B), while TechnipFMC plc Ordinary Share trades at $69.36 (market cap $27.73B). The key difference: TechnipFMC plc Ordinary Share is far larger — about 7× Edgewise Therapeutics Inc. Common Stock's market cap, and TechnipFMC plc Ordinary Share pays a 0.28% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and TechnipFMC plc Ordinary Share for 6 Days on average.
| EWTX | FTI | |
|---|---|---|
Market Cap | $3.94B | $27.73B |
Volume | 810,104 | 2,487,618 |
Sector | Health | Energy |
52-Week High | $48.35 | $80.08 |
52-Week Low | $14.89 | $35.57 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $3.48B | $27.98B |
Dividend Yield | — | 0.28% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FTI trades at $70.72, up 1.39% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 36.04% ROE and 11.28% net margin. Recent Petrobras contract wins and strategic hires strengthen its subsea and consulting capabilities. Analyst consensus remains bullish with a $80.50 price target representing 14% upside potential.
FTI presents a compelling growth story with consistent earnings outperformance and strategic expansion, though technical indicators suggest near-term consolidation. The primary risk involves execution of recent contracts and maintaining profitability amid rising expenses. With zero sell ratings and institutional accumulation, the stock offers upside potential for investors comfortable with energy sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →